



SUPPLEMENT APPROVAL

December 7, 2022

ADMA Biologics, Inc.
Attention: James Maloney
5800 Park of Commerce Boulevard, N.W.
Boca Raton, FL 33487

Dear Mr. Maloney:

We have approved your requests received on August 9, 2022, to supplement your Biologics License Applications (BLAs) submitted under section 351(a) of the Public Health Service Act, to include room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life, for the following products:

STN	Name of Biological Products
BL 125590/100	Immune Globulin Intravenous, Human-slra
BL 125389/284	Immune Globulin Intravenous (Human)

We also refer to our supplement approval letter dated December 2, 2022, which contained the following error:

- Reference to labeling was not included in the supplement approval letter

This replacement approval letter incorporates the correction of the error. The effective approval date will remain December 2, 2022, the date of the original supplement approval letter.

We have approved your request submitted August 9, 2022, to supplement your Biologics License Application (BLAs) under section 351(a) of the Public Health Service Act for Immune Globulin Intravenous, Human-slra and Immune Globulin Intravenous (Human) to include room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life for ASCENIV and BIVIGAM.

LABELING

We hereby approve the draft content of labeling, Package Insert submitted under amendment 1 dated October 10, 2022, and received on October 11, 2022, and the draft carton and container labels, submitted under amendment 3 on October 21, 2022, and received on October 24, 2022.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the: Package Insert, submitted on October 10 2022. Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELS

Please electronically submit final printed carton and container labels identical to the carton and container labels submitted on October 21, 2022, according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications>.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125590 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

Please submit an amendment to all pending supplemental applications for these BLAs that include revised labeling incorporating a revised content of labeling that includes these changes.

We will include information contained in the above-referenced supplement in your BLA files.

Sincerely,

Basil Golding, MD
Director
Division of Plasma Protein Therapeutics
Office of Tissues and Advanced Therapies
Center for Biologics Evaluation and Research